Trial · NCT04315285
Optimal Verbal Instruction to Improve Walking for PD
NCT04315285, Not applicable, Completed, National Taiwan University Hospital
3 sourcestrials-2026-11-12-0.4.0
Download JSON
Cite this record
ConductScience Library. Optimal Verbal Instruction to Improve Walking for PD. Trials, record NCT04315285. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04315285
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Optimal Verbal Instruction to Improve Walking for PD
- NCT number
- NCT04315285
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 35 participants, actual
- Lead sponsor
- National Taiwan University Hospital
- Conditions
- Parkinson Disease, Gait Disorders, Neurologic
- Interventions
- Treadmill gait training with verbal instruction
- First posted
- 2020-03-19
- Last updated
- 2024-02-20
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Gait performances | Three time points: pre-test(before intervention), post-test(immediate after intervention), follow-up test(one month after intervention) | The participants will be required to walk along a 5-meter walkway in their comfortable walking speed for 5 trials under single and dual-task walking conditions. The gait performances will be captured by the Physilog®5 system (Gait Up, Renens, Switzerland), which include two inertial sensors with built-in 3D accelerometers and gyroscopes. |
| Secondary | Montreal Cognitive Assessment (MoCA) | Three time points: pre-test(before intervention), post-test(immediate after intervention), follow-up test(one month after intervention) | The MoCA will be used to evaluate general cognitive function of the participants. It evaluates several cognitive functions including attention, set-shifting, short-term memory, verbal fluency, calculation, orientation, digit span, conceptual thinking, and visuospatial processing skills. The total score of MoCA is 30 with a higher score indicating better cognitive function. The MoCA has good to excellent psychometric properties |
| Secondary | The Stroop Color-Word test | Three time points: pre-test(before intervention), post-test(immediate after intervention), follow-up test(one month after intervention) | The Stroop Color-Word test will be used to evaluate the changes in executive functions in people with PD. The executive functions involved in the Stroop Color-Word test are selective attention, inhibition, and set-shifting. The Stroop Color-Word test comprises the congruent and incongruent testing conditions. The congruent condition is when the color ink of a word is coherent with the written color name, and the incongruent condition is when the color ink differs from the written color name (e.g., the word 'red' written in blue ink). The participants are instructed to read out the ink color of the word, but not the color word name, as accurately and as fast as possible within 45 seconds. |
| Secondary | The Unified Parkinson's Disease Rating Scale (UPDRS) | Three time points: pre-test(before intervention), post-test(immediate after intervention), follow-up test(one month after intervention) | The Unified Parkinson's Disease Rating Scale (UPDRS) is a well-established and widely used rating tool for the evaluation of disease severity of PD. The UPDRS consists of 4 sections: 1) Mentation, Behavior, and Mood, 2) Activities of daily living (ADL), 3) Motor examination, and 4) Complications of therapy. In this proposed study, we will only evaluate Part 3 of the scale - the motor disturbances of the patients. The section of "motor examination" contains 18 tests with 33 items (some tests contain movement of the left and right extremities and/or trunk), and each item scores from 0 (absent of the symptom) to 4 (marked in the symptom and present most of the time). The total score ranges from 0 to 132 for Part 3 of the UPDRS with a lower score indicates less PD symptoms and a higher score suggests more severe in PD disease. Internal consistency and validity has been established to be excellent for UPDRS. |
| Secondary | Fatigue severity questionnaire (FSS) | Three time points: pre-test(before intervention), post-test(immediate after intervention), follow-up test(one month after intervention) | The FSS will be used to determine how fatigue interferes an individual's daily living and social participation. It contains 9 items, and each item is scored on a 7-point scale with a score 1 indicates strongly disagree and score 7 indicates strongly agree. The total score ranges from 9 to 63, with a higher score indicate greater fatigue severity. |
| Secondary | Parkinson's Disease Questionnaire-39 (PDQ-39) | Three time points: pre-test(before intervention), post-test(immediate after intervention), follow-up test(one month after intervention) | The PDQ-39 is a self-report questionnaire containing 39 items assessing the impact of PD on quality of life. The PDQ-39 covers 8 dimensions: mobility, activities of daily living, emotional well-being, stigma, cognition, communication, and bodily discomfort. The participants are required to answer the questions based on their experiences in the preceding month prior to the interview. The scoring system for each item ranges from 0 (never have difficulty) to 4 (always have difficulty) with lower scores suggesting better quality of life. |
| Secondary | New Freezing of Gait Questionnaire (NFOG-Q) | Three time points: pre-test(before intervention), post-test(immediate after intervention), follow-up test(one month after intervention) | The NFOG-Q will be used to evaluate the freezing frequency and severity of the patients with PD. It composes of 3 parts; in the first part, a video clip will be shown to the participants with PD and help to classify whether an individual is a freezer or non-freezer. The second and third part of the questionnaire is designed for freezers only. PartⅡassesses the severity of FoG according to the frequency and duration of the freezing episodes, while PartⅢevaluates the impact of freezing on daily activities, such as walking. The reliability and internal consistency of the NFOG-Q have been well-established for patients with PD. |
| Secondary | Geriatric Depression Scale (GDS) | Three time points: pre-test(before intervention), post-test(immediate after intervention), follow-up test(one month after intervention) | The GDS is a self-report measure of depression in older adults. The GDS contains 15 items, and the users respond in a "Yes/No" format to each question in reference to the past 1 week. |
| Secondary | The Timed Up and Go (TUG) Test | Three time points: pre-test(before intervention), post-test(immediate after intervention), follow-up test(one month after intervention) | The participants will initially sit on a comfortable chair with hips and knees flexed at 90°. Upon a 'GO' signal, the participants will stand up from the chair, walk for 3 meters, turn around, walk back to the chair, and sit down. The participants will be instructed to complete the task at their preferred/ comfortable speed. Good to excellent test-retest reliability and inter-rater reliability have been established in people with PD. |
| Secondary | Finger sequence task | Three time points: pre-test(before intervention), post-test(immediate after intervention), follow-up test(one month after intervention) | A finger sequence task will be used to evaluate motor learning ability. The finger sequence task contains 3 numerical sequences, and each sequence is embedded with colored circles and presented on a specific location on the computer screen. The participants will not be informed about the specific sequence-context associations; they will only be instructed to use their index and middle finger of both hands to press the keys for the numerical sequences in a sequential order of 1-2-3-4 as accurately and as fast as possible. The 3 sequences will be presented on the computer screen in a pseudorandom order, and the participants will be required to complete a total of 324 trials (108 trials per sequence) during the acquisition period. Ten minutes and 24 hours after practice, the participants will be tested under different testing conditions. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 38207195 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Secondary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
| Verbal Fluency | Secondary outcome | ConductCognition |
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04315285
GET https://conductscience.org/api/trials/v1/NCT04315285/registered